- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07946627
Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Lowell B Anthony, MD
- Puhelinnumero: 859-257-4488
- Sähköposti: lan225@uky.edu
Opiskelupaikat
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40536
- University of Kentucky
-
Ottaa yhteyttä:
- Lowell B Anthony, MD
- Puhelinnumero: 859-257-4488
- Sähköposti: lan225@uky.edu
-
Päätutkija:
- Lowell B Anthony, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm).
- Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver.
- Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established.
- Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have received a specific therapy prior to enrollment. Patients will take everolimus leading up to the embolization once enrolled in the study. They will only be enrolled in the study for their first hepatic artery embolization. They must be 30 days out since their last cancer treatment of any kind, not including somatostatin analogs.
- Age ≥18 years.
- ECOG performance status ≤2 (see Appendix A).
- Patients must have adequate organ and marrow function as defined below:
- absolute neutrophil count ≥1,000/mcL
- platelets ≥100,000/mcL
- total bilirubin ≤ institutional upper limit of normal (ULN)
- Child-Turcotte-Pugh class A; B dose reduction is recommended at 5mg QD or less; C recommend non-usage of everolimus
- Creatinine (or GFR) ≤ institutional ULN (Appendix B)
- GFR, glomerular filtration rate (or creatinine) There are no dose reductions required for patients in any stage of renal failure for everolimus
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
- Prior transhepatic artery embolization.
- Contraindication to arteriography or embolization.
- Prior chemotherapy or peptide receptor radionuclide therapy within 1 month.
- Biliary stent or choledocho-enteric anastomosis.
- Patients who are receiving any other investigational agents for the treatment of this cancer.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
- Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Drug-drug interactions of risk level X will be excluded from the trial unless an alternative medication can be substituted. Drug-drug interactions are classified into classes A, B, C, D and X. A Class X drug interaction represents a high-risk, contraindicated combination where the risks of taking the medications together clearly outweigh any potential benefits. These medications include Antihepaciviral Combination Products, BCG Products, Brivudine, Chikungunya Vaccine (Live), Chloramphenicol (Systemic), Cladribine, Dengue Tetravalent Vaccine (Live), Etrasimod, Fexinidazole, Grapefruit Juice, Inhibitors of CYP3A4 (Strong) and P-glycoprotein, Mumps- Rubella- or Varicella-Containing Live Vaccines, Nadofaragene Firadenovec, Natalizumab, Pimecrolimus, Pimozide, Poliovirus Vaccines (Live/Oral), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Thiamphenicol, Typhoid Vaccine, Vaccines (Live), Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated). Additionally, patients should avoid taking everolimus while on strong CYP3A4 inhibitors. They should have everolimus dose reduction to 2.5 mg PO while on moderate CYP34A inhibitors and/or PgP inhibitors. An increase in everolimus dose is recommended when co-administered with a strong CYP3A4 inducer (see package insert, Appendix C).
- Patients with uncontrolled intercurrent illness.
- Pregnant women are excluded from this study because everolimus is an mTOR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus, breastfeeding should be discontinued if the mother is treated with everolimus. NOTE: Patients treated with everolimus should use highly effective birth control during treatment and for 8 weeks after their last everolimus dosing. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with everolimus and for 4 weeks after the last dose
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Everolimus following Bland Hepatic Artery Embolization
Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization. Bland Hepatic Artery procedure will occur on Day 0. |
Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization Bland Hepatic Artery Embolization (HAE) will occur on Day 0. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of patients who can tolerate everolimus pre and post HAE
Aikaikkuna: Pre-study to Day 30
|
To assess the percentage of patients who can tolerate ½ pre-embolization everolimus dose administered every other day post-bland hepatic artery embolization of liver metastasis in neuroendocrine tumor (NET) patients (dose optimization trial). |
Pre-study to Day 30
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Objective Response Rate
Aikaikkuna: Pre-study to Day 30
|
To determine the objective response rate (ORR) and hepatic progression-free survival (hPFS). |
Pre-study to Day 30
|
|
Progression Free Survival
Aikaikkuna: Pre-study to Day 30
|
To determine the objective response rate (ORR) and hepatic progression-free survival |
Pre-study to Day 30
|
|
Biochemical Response
Aikaikkuna: Pre-study to Day 30
|
To evaluate biochemical response using Chromogranin A (CGA), serotonin, and 5-HIAA levels, defined as a 50% reduction from baseline if elevated. |
Pre-study to Day 30
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Lowell B Anthony, MD, University of Kentucky
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 120321
- MCC-26-GI-150 (Muu tunniste: University of Kentucky)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .